Friday,
September 15, 2017
Check-in & Dinner: 5:45 pm
Program: 6:10 pm - 8:00 pm

Hyatt Regency San Francisco
Room: Seacliff Room, Bay Level
5 Embarcadero Center, San Francisco, CA 94111

A satellite program at
AHA Council on Hypertension
AHA Council on Kidney in Cardiovascular Disease
American Society of Hypertension
Joint Scientific Sessions 2017

Sponsored by Cardiovascular Research Foundation
Supported through an educational grant from Medtronic

Overview

Hypertension is the most common modifiable risk factor for cardiovascular disease and loss of life. In order to reduce organ damage and prevent cardiovascular disease, controlling blood pressure in those with hypertension is necessary. When lifestyle modification and antihypertensive medication do not work, additional approaches are necessary. Interventional approaches such as transcatheter renal denervation (RDN) have been evaluated but not yet proven to be beneficial in reducing blood pressure when a sham-controlled arm was part of the protocol.

This educational program will discuss the latest data and evidence on RDN, insights on the advances in interventional hypertension therapies, and the ongoing studies in the renal denervation space. Expert presenters will review the scientific bases for RDN, lessons learned from previous trials, where we stand on resistant hypertension, and what the most recent RDN trial results have found. Ample time will be allowed for audience Q&A.

To attend this Satellite Program, you must be registered for AHA Council on Hypertension, AHA Council on Kidney in Cardiovascular Disease and American Society of Hypertension Joint Scientific Sessions 2017. Please bring your AHA badge with you and have it scanned in the room to note your attendance. Seats are first-come, first-served.

Learning Objectives

By the end of this program, participants will be able to:

  • Summarize the latest evidence and data from studies on transcatheter renal denervation procedures.
  • Identify the advances in interventional hypertension therapies and the benefits to patients that are not controlled with antihypertensive medications.
  • Discuss findings from recent clinical trials on resistant hypertension.

The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cardiovascular Research Foundation designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity is designed for hypertension specialists (cardiologists/nephrologists), basic science researchers and other healthcare professionals involved in the management of patients with cardiovascular disease.

Evaluation by questionnaire will address content, presentation effectiveness, possible bias, and future educational needs.

It is the policy of the Cardiovascular Research Foundation to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and therefore, does not compromise the scientific integrity of the educational activity.

Discussion of off-label product usage is made at the sole discretion of the faculty. Off-label product discussion and usage is not endorsed by the Cardiovascular Research Foundation or the course directors of this activity.

Faculty participating in continuing medical education activities sponsored by the Cardiovascular Research Foundation are required to disclose to the activity audience any real or apparent conflicts of interest related to the content of their presentations. Faculty in noncompliance with this policy are not permitted to participate in this activity.

This program is sponsored by the Cardiovascular Research Foundation and supported through an educational grant from Medtronic. The Cardiovascular Research Foundation ensures that its programs are educational and meet the needs of the target audience. This program was developed without influence from commercial supporters.

Faculty

CHAIR

Jan N. Basile, MD Seinsheimer Cardiovascular Health Program
Medical University of South Carolina
Ralph H. Johnson VA Medical Center
Charleston, SC

Invited Faculty

Debbie L. Cohen, MD Hospital of the University of Pennsylvania
Philadelphia, PA

Raymond R. Townsend, MD Hospital of the University of Pennsylvania
Philadelphia, PA

John W. Osborn, PhD University of Minnesota
Minneapolis, MN

Michael A. Weber, MD SUNY Downstate Medical Center
Brooklyn, NY

Agenda

6:10 pm

IntroductionJan N. Basile

6:15 pm

The Scientific Basis for Renal Denervation John W. Osborn

6:35 pm

Lessons Learned on Drugs, Populations, and Procedures From Past Renal Denervation Trials Debbie L. Cohen

6:55 pm

What Have We Learned on Treating Resistant Hypertension Since HTN-3? Michael A. Weber

7:15 pm

SPYRAL HTN Clinical Program Raymond R. Townsend

7:35 pm

Q&A with Audience Panel

8:00 pm

Adjourn

REGISTER

Should you have any questions, please contact
Ryo Mochido at rmochido@crf.org.

Register Now